利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.028 秒)

    Cancer associated antigens, sga-56m and sga-56mv, and uses thereof
    1.
    发明申请
    Cancer associated antigens, sga-56m and sga-56mv, and uses thereof 审中-公开
    癌症相关抗原，sga-56m和sga-56mv及其用途

    公开(公告)号：US20060121476A1

    公开(公告)日：2006-06-08

    申请号：US10527572

    申请日：2003-09-12

    申请人： Joseph Petroziello ,  Che-Leung Law ,  Andrew Yamane ,  Alan Wahl

    发明人： Joseph Petroziello ,  Che-Leung Law ,  Andrew Yamane ,  Alan Wahl

    IPC分类号： C12Q1/68 ,  G01N33/574

    CPC分类号： G01N33/57415 ,  C07K14/4748

    摘要： The present invention relates to nucleic and amino acid sequences of SGA-56M and variants thereof. An exemplary variant of SGA-56M is SGA-56Mv. SGA-56M and SGA-56Mv are differentially expressed in cancer tissues and transformed cell lines. In particular, these genes are expressed at elevated levels in breast cancer and lung cancer tissues and cell lines. The present invention is also directed to methods for diagnosing a cancer in a subject, determining the prognosis of a cancer patient, and/or monitoring the efficacy of a treatment regimen for a cancer patient. The present invention further provides methods for screening and identifying modulators (e.g., antagonists or agonists) of SGA-56M and/or SGA-56Mv expression and/or activity. Antagonists identified using the methods of the invention are useful for the treatment of cancer patients. Also encompassed by the present invention are compositions including nucleic and/or amino acid sequences of SGA-56M and SGA-56Mv or SGA-56M/SGA-56Mv modulators and a pharmaceutically acceptable carrier. Such compositions may be used to advantage to treat a subject with a cancer to ameliorate the symptoms of the cancer or reduce the cancer cell burden in the subject. These compositions may also be utilized to prevent or delay the onset of a cancer in a subject exhibiting a predisposition to developing a cancer.

    摘要翻译： 本发明涉及SGA-56M的核酸和氨基酸序列及其变体。 SGA-56M的示例性变体是SGA-56Mv。 SGA-56M和SGA-56Mv在癌组织和转化细胞系中差异表达。 特别地，这些基因在乳腺癌和肺癌组织和细胞系中以升高的水平表达。 本发明还涉及用于诊断受试者中的癌症的方法，确定癌症患者的预后和/或监测癌症患者的治疗方案的功效。 本发明还提供筛选和鉴定SGA-56M和/或SGA-56Mv表达和/或活性的调节剂（例如拮抗剂或激动剂）的方法。 使用本发明方法鉴定的拮抗剂可用于治疗癌症患者。 本发明还包括包含SGA-56M和SGA-56Mv或SGA-56M / SGA-56Mv调节剂的核酸和/或氨基酸序列和药学上可接受的载体的组合物。 这样的组合物可用于治疗患有癌症的受试者以改善癌症的症状或降低受试者的癌细胞负担。 也可以利用这些组合物来预防或延迟患有发展为癌症倾向的受试者的癌症的发作。

    Sga-1m, a cancer associated antigen, and uses thereof
    2.
    发明申请
    Sga-1m, a cancer associated antigen, and uses thereof 审中-公开
    Sga-1m，癌相关抗原及其用途

    公开(公告)号：US20070128593A1

    公开(公告)日：2007-06-07

    申请号：US10503462

    申请日：2003-02-03

    申请人： Joseph Petroziello ,  Che-Leung Law ,  Alan Wahl

    发明人： Joseph Petroziello ,  Che-Leung Law ,  Alan Wahl

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C07K14/47 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  G01N33/5011 ,  G01N33/57484 ,  G01N2500/00

    摘要： The present invention relates to a gene and gene product, SGA-1M that is differentially expressed in cancer tissues and cell lines. Suppression Subtractive Hybridization and microarray screening were used to screen for differential expression of SGA-1M in cancer tissues and cell lines. Expression analysis has demonstrated overexpression of SGA-1M in breast cancer tissue and breast cancer derived cell lines, in ovarian cancer, skin cancer, a cancer of the lymphoid system, thyroid cancer, pancreatic cancer, stomach cancer, and lung cancer. The gene is expressed as a 1.95 kb mRNA. The full length cDNA comprises two open reading frames encoding polypeptides of 221 and 75 amino acids, respectively. Monitoring expression levels of SGA-1M is useful for the diagnosis and prognosis of cancer as well as for evaluating the risk of developing certain types of cancers and the risk of metastasis of cancer. Reagents that target SGA-1M are useful for the treatment of cancer.

    摘要翻译： 本发明涉及在癌组织和细胞系中差异表达的基因和基因产物SGA-1M。 抑制消减杂交和微阵列筛选用于筛选癌组织和细胞系中SGA-1M的差异表达。 表达分析已经证明SGA-1M在乳腺癌组织和乳腺癌衍生细胞系，卵巢癌，皮肤癌，淋巴系统癌症，甲状腺癌，胰腺癌，胃癌和肺癌中的过度表达。 该基因表达为1.95kb的mRNA。 全长cDNA分别包含编码221和75个氨基酸的多肽的两个开放阅读框。 监测SGA-1M的表达水平对于癌症的诊断和预后以及评估发展某些类型癌症的风险和癌症转移的风险是有用的。 靶向SGA-1M的试剂可用于治疗癌症。

    Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
    7.
    发明申请
    Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders 审中-公开
    抗CD20抗体 - 药物共轭物，用于治疗癌症和免疫疾病

    公开(公告)号：US20050180972A1

    公开(公告)日：2005-08-18

    申请号：US10632151

    申请日：2003-07-30

    申请人： Alan Wahl ,  Peter Senter ,  Che-Leung Law ,  Charles Cerveny

    发明人： Alan Wahl ,  Peter Senter ,  Che-Leung Law ,  Charles Cerveny

    IPC分类号： A61K39/395 ,  A61K47/48 ,  C07K16/46

    CPC分类号： A61K47/6851 ,  A61K47/6849

    摘要： The present invention relates to methods and compositions for the treatment of CD20-expressing cancers and immune disorders involving CD20-expressing cells. The present methods comprise administering to a subject an anti CD20 antibody-drug conjugate that has a high potency and/or is capable of internalizing into CD20-expressing cells. The present invention further provides pharmaceutical compositions and kits comprising such conjugates. The present invention yet further provides methods of and compositions relating to combination therapy of cancer and immune disorders involving CD20-expressing cells using the anti-CD20 antibody-drug conjugates of the invention.

    摘要翻译： 本发明涉及用于治疗表达CD20的癌症和涉及CD20表达细胞的免疫疾病的方法和组合物。 本发明的方法包括向受试者施用具有高效力和/或能够内化成CD20表达细胞的抗CD20抗体 - 药物偶联物。 本发明还提供了包含这种缀合物的药物组合物和试剂盒。 本发明还进一步提供了使用本发明的抗CD20抗体 - 药物共轭物的癌症和涉及CD20表达细胞的免疫疾病的组合疗法的方法和组合物。

    Recombinant Anti-Cd30 Antibodies and Uses Thereof
    10.
    发明申请
    Recombinant Anti-Cd30 Antibodies and Uses Thereof 审中-公开
    重组抗Cd30抗体及其用途

    公开(公告)号：US20070258987A1

    公开(公告)日：2007-11-08

    申请号：US10558811

    申请日：2004-05-28

    申请人： Joseph Francisco ,  Grant Risdon ,  Alan Wahl ,  Clay Siegall ,  Peter Senter ,  Doronina Svetlana ,  Brian Toki

    发明人： Joseph Francisco ,  Grant Risdon ,  Alan Wahl ,  Clay Siegall ,  Peter Senter ,  Doronina Svetlana ,  Brian Toki

    IPC分类号： A61K39/395 ,  A61P35/00

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/73

    摘要： The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.

    摘要翻译： 本发明涉及用于治疗霍奇金病的方法和组合物，其包括给予特征为结合CD30的能力的蛋白质，或与单克隆抗体AC10或HeFi-1竞争结合CD30，并对细胞生长抑制或细胞毒性作用 霍奇金病细胞在没有效应细胞或补体的情况下。 这些蛋白质包括单克隆抗体AC10和HeFi-1的衍生物。 本发明的蛋白质可以是人，人源化或嵌合抗体; 此外，它们可以与细胞毒性剂如化学治疗药物缀合。 本发明还涉及编码本发明蛋白质的核酸。 本发明还涉及用于鉴定可用于治疗或预防霍奇金病的抗CD30抗体的方法。